A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

NCT02432326 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Advanced Solid Tumors

Interventions

DRUG: BBI608
DRUG: BBI503

Sponsor

Sumitomo Pharma America, Inc.